BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.90
+0.03 (0.38%)
Jan 31, 2025, 4:00 PM EST - Market closed
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for BCRX stock have an average target of 15.5, with a low estimate of 8.00 and a high estimate of 30. The average target predicts an increase of 96.20% from the current stock price of 7.90.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BCRX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $18 | Buy | Reiterates | $18 | +127.85% | Jan 31, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $10 → $12 | Buy | Maintains | $10 → $12 | +51.90% | Jan 13, 2025 |
| Needham | Needham | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +89.87% | Jan 13, 2025 |
| Needham | Needham | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +89.87% | Dec 17, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +26.58% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
458.80M
from 331.41M
Increased by 38.44%
Revenue Next Year
556.22M
from 458.80M
Increased by 21.23%
EPS This Year
-0.37
from -1.18
EPS Next Year
-0.09
from -0.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 476.7M | 585.6M | 697.7M | |||
| Avg | 458.8M | 556.2M | 633.3M | |||
| Low | 436.5M | 502.7M | 553.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 43.8% | 27.6% | 25.4% | |||
| Avg | 38.4% | 21.2% | 13.9% | |||
| Low | 31.7% | 9.6% | -0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.32 | 0.12 | 0.58 | |||
| Avg | -0.37 | -0.09 | 0.29 | |||
| Low | -0.43 | -0.24 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.